V. Thompson

Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial.

H. White, E. Ohman, J. Alexander, 2013, Cardiology Journal.

Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y(12)-receptor inhibitor, versus clopidogrel to eVAluate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI

Deepak L. Bhatt, Sunil V. Rao, K. Huber, 2010, American heart journal.

Effects of Once‐Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

Neha J. Pagidipati, B. Zinman, R. Holman, 2017, The New England journal of medicine.

A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y12 Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention: The INNOVATE-PCI Trial

Deepak L. Bhatt, Sunil V. Rao, K. Huber, 2012, Circulation. Cardiovascular interventions.

Changes in Serum Calcitonin Concentrations, Incidence of Medullary Thyroid Carcinoma, and Impact of Routine Calcitonin Concentration Monitoring in the EXenatide Study of Cardiovascular Event Lowering (EXSCEL)

R. Holman, Adrian F. Hernandez, J. Buse, 2019, Diabetes Care.

Usefulness of the Duke Sudden Cardiac Death risk score for predicting sudden cardiac death in patients with angiographic (>75% narrowing) coronary artery disease.

R. Califf, L. Shaw, M. Roe, 2009, The American journal of cardiology.

Baseline characteristics of patients enrolled in the Exenatide Study of Cardiovascular Event Lowering (EXSCEL)

Neha J. Pagidipati, B. Zinman, R. Holman, 2017, American heart journal.

Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease.

R. Holman, A. Kong, N. Sattar, 2018, Circulation.